Nichi-Iko Falls Short Of Target
But Remains Upbeat On Recent US Launches
Despite seeing sales through its US Sagent unit hit by supply issues with CMOs, Nichi-Iko says its US profits have increased on the back of newly-launched products. However, this failed to offset the impact of NHI price revisions in Japan, dragging down profits in the first nine months of the year.
You may also be interested in...
Nichi-Iko is exploring the possibility of a joint venture with digital services provider MedPeer, building on a collaboration that the Japanese generics firm believes will represent a “new generic drugs business model.”
Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.
Nichi-Iko is set to obtain by 1 April next year all shares in Eisai’s Elmed Eisai value-added generic pharmaceuticals business in Japan, while Nichi-Iko and Elmed Eisai also plan to “integrate their strengths” and co-promote one another’s generic products in the country, as part of a broader, three-part, strategic alliance agreement.